<DOC>
	<DOCNO>NCT02927509</DOCNO>
	<brief_summary>Aim : To describe 1 ) The use TNF blocker early arthritis daily clinical practice France 2 ) To evaluate symptomatic , structural efficacy , retention rate 5 year 3 ) To evaluate predictive factor TNF blocker response Type study : Observational cohort study use cross-section longitudinal data . Description project methodology - Patients : All patient ESPOIR cohort ( multicentre French cohort study early RA ) .A sub-analysis conduct among patient satisfy ACREULAR 2010 criterion . - Data collect : Patient characteristic , Clinical data regard RA related pathology , Characteristics treatment receive The analysis conduct use data collect baseline , 6 , 12 , 18 , 24 , 36 , 48 , 60 month . - Analyses : 1 . Frequency use TNF blocker : % patient initiate TNF blocker calculate ( Kaplan-Meier method ) , type TNF blocker describe , route administration , dosage , association DMARDs place TNF blocker treatment strategy first 5 year . 2 . Implementation EULAR recommendation : percentage patient initiate TNF blocker meet EULAR criterion initiation estimate , concordance coefficient Kappa regard fulfilment initiation TNF blocker calculate , disease severity outcome measure compare depend fulfilment . 3 . Identification potential predictive factor initiation TNF blocker : survival curve ( Kaplan-Meier ) perform . The baseline characteristic patient regard initiation TNF blocker first 5 year disease compare univariate analysis Log-rank test perform variable . A stepwise multivariate analysis ( Cox analysis ) perform . 4 . Therapeutical effect : retention rate time calculate , change different variable compare group patient receive TNF blocker match ( use propensity score ) 1,2 3 patient . The DAS28 HAQ assess compare short term ( least 8 week treatment ) long term ( last available visit ) group . The structural efficacy evaluate radiographic progression last available visit.The drug effect identically estimate depend TNF blocker use , calculate retention rate compare DAS28 short term long term . 6 ) Identification predictive factor TNF blocker response : To evaluate impact baseline demographic disease condition DAS28 HAQ response first 5 year compare univariate multivariate analysis . Expected result : Increase knowledge optimal use TNF blocker predictive factor TNF blocker response early RA patient .</brief_summary>
	<brief_title>Evaluation Tumour Necrosis Factor Alpha ( TNFÎ± ) Blockers Early Rheumatoid Arthritis France</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>age 18 70 year 2 swollen joint &gt; 6 week &lt; 6 month suspect confirmed diagnosis RA previous intake DMARDs steroid ( except &lt; 2 week ) . Patients exclude refer physician judge clearly define inflammatory rheumatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>